Elicio Therapeutics Inc ELTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Elicio Therapeutics to Host Virtual KOL Event on November 11, 2026: ELI-002 7P for Metastatic and Neoadjuvant PDAC
Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting
Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results at ESMO Congress 2026 and Announces Simultaneous Publication in Nature Medicine
Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026
Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference
Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
Trading Information
- Previous Close Price
- $1.50
- Day Range
- $1.44–1.59
- 52-Week Range
- $1.25–16.00
- Bid/Ask
- $1.44 / $1.49
- Shares Outstanding
- 28.31M
- Market Cap
- $41.05M
- Volume/Avg
- 231,645 / 322,525
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 33
- Website
- https://www.elicio.com
Valuation
Metric | ELTX |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | ELTX |
|---|---|
Quick Ratio | 3.11 |
Current Ratio | 3.43 |
Interest Coverage | −22.24 |
Quick Ratio
ELTX
Profitability
Metric | ELTX |
|---|---|
Return on Assets (Normalized) | −120.39% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −169.93% |
Return on Assets
ELTX
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|KS<!t^ | LOCK|s$N& | $131B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|GK!MDqb | LOCK|^S<yL | $95B | |||
| Moderna Inc MRNA | LOCK|&%?w^#b | LOCK|Mc | $79B | |||
| argenx SE ADR ARGX | LOCK|D@?@Gf | LOCK|Wb | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|>YQpH? | LOCK|%<x | $45B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|JpT$!F$ | LOCK|br<@ | $30B | |||
| Incyte Corp INCY | LOCK|%q&^SG> | LOCK|!@ | $23B | |||
| BioNTech SE ADR BNTX | LOCK|py>%>JS | LOCK|X!! | $20B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|x>Q@K? | LOCK|hM#n | $19B | |||
| BridgeBio Pharma Inc BBIO | LOCK|s>#<YR | LOCK|QrP | $15B |